Navigation Links
EAU Position Statement on Screening for Prostate Cancer
Date:4/16/2009

ARNHEM, The Netherlands, April 16 /PRNewswire/ -- The European Association of Urology (EAU) has taken into consideration the recent scientific information on randomised screening studies on prostate cancer (Schröder et al, NEJM 2009). Based on the results of the European Randomised Study for Screening of Prostate Cancer (ERSPC), the EAU has formulated a position statement regarding prostate cancer screening in Europe, and the subsequent actions to be taken by health professionals and health authorities.

In summary, the ERSPC reports on a relative prostate cancer mortality reduction of at least 20% by PSA-based population screening in 162,000 asymptomatic men aged 55-69 years. For every prostate cancer death prevented, 1410 men have to undergo screening, while 48 are needed to be treated in excess of the control group population to save one prostate cancer death. Results of the PLCO (Prostate, Lung, Colon and Ovary) US randomized study of screening were also published in the same issue of the NEJM (Andriole et al, NEJM 2009) and to date show no significant effect of screening on mortality from the disease, but suffered from a significant level of contamination in the control arm. The study continues.

The EAU adopts the conclusions of the ERSPC study and recognizes the benefit of screening in terms of mortality reduction, as well as the adverse effects of overdiagnosis and overtreatment of prostate cancers which could be quantified for the first time in the setting of a randomized screening study. Further publication of relevant data is awaited from the ERSPC group in due course to inform the debate.

For the interest men's health in Europe and elsewhere, the EAU formulates the following statements:

    - Prostate cancer is a major health problem, and one of the
    main causes of male cancer deaths. However, current published data are
    insufficient to recommend the adoption of population screening for
    prostate cancer as a public health policy due to the large overtreatment
    effect. Before screening is considered by national health authorities,
    the level of current opportunistic screening, overdiagnosis,
    overtreatment, quality of life, costs, and cost-effectiveness should be
    taken into account.
    - Overdiagnosis of prostate cancer leads potentially to significant
    overtreatment. Health professionals, especially urologists, should avoid
    overtreatment by developing safe methods of cancer
    surveillance/monitoring without invasive therapy. Invasive therapies
    should be tailored to patients' needs and the prognosis of cancers
    diagnosed.
    - Current screening algorithms are insufficient due to a lack of
    specificity and lack of selectivity for aggressive cancers which require
    treatment. The development of novel diagnostic and prognostic markers and
    imaging modalities is needed urgently to enhance the predictive value of
    screening tools.
    - In the absence of population screening, the EAU advises men who
    consider screening by PSA testing and prostate biopsy to obtain
    information on the risks and benefits of screening and individual risk
    assessment.
    - The EAU and the ERSPC study group represent essential European
    stakeholders to further develop health strategies for prostate cancer
    screening.
    - The EAU promotes the quality of care for prostate cancer patients
    in Europe in collaboration with the patient support organization Europa
    Uomo http://www.europa-uomo.org) through the development of information
    and guidelines.
    - The EAU wishes to support and foster research needed to develop
    reliable active surveillance protocols for low-risk prostate cancers,
    prognostic markers, and targeted therapies in order to deliver optimal
    patient care.



'/>"/>
SOURCE European Association of Urology
Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

1. Kibow Biotech Obtains Australian, Chinese and Indian Patents Protecting the Composition and Basic Technology Behind Its Oral Probiotic Formulation for Chronic Kidney Failure
2. Coalition for 21st Century Medicine Issues Statement in Opposition of Genentech Petition to Restrict Lab Use of Diagnostic Tests for Physicians and Patients
3. AAOMS Updates BRONJ Position Paper
4. Amicus Therapeutics Announces Issuance of New Plicera(TM) Composition of Matter Patent
5. Statement by KCP Chairman Dr. Edward Jones in Response to FDA Advisory Committee on Benefits and Risks of Erythropoietin-Stimulating Agents in Treatment of Kidney Patients
6. Statement From The National Conclave on HIV/AIDS Policy for Black Clergy
7. Statement by US Oncology on FDA Label on Erythropoiesis Stimulating Agents (ESAs)
8. AIDS Action Council Statement on World AIDS Day 2007: Leadership Needed for a National Strategy to Stop the AIDS Epidemic
9. Statement of Andrea Kavanagh, Director, Pure Salmon Campaign, on the Science Sea Lice Study
10. Statement from the American Diabetes Association Related to ACCORD Trial Announcement
11. Media Statement: MHA Keystone Center for Patient Safety & Quality OHRP Ruling
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/12/2017)... and Company (NYSE: LLY ) has entered into ... litigation in the U.S. District Court for the Eastern District ... (tadalafil) unit dose patent. This patent was previously set ... agreement, Cialis exclusivity is now expected to end at the ... patent for Cialis is valid and infringed by companies seeking ...
(Date:7/11/2017)... 11, 2017  The global market for liquid biopsy ... $394.1 million in 2016.  Although in early stages, the ... in particular as a result of the gradual shift ... recent introduction of a significant number of new liquid ... of tumor biomarkers to guide treatment decisions. ...
(Date:7/11/2017)... July 11, 2017 Oramed Pharmaceuticals Inc. (NASDAQ: ... pharmaceutical company focused on the development of oral drug ... Drug Administration (FDA) has agreed to schedule an End-of-Phase ... IIb trial of its oral insulin capsule ORMD-0801 in ... trial met primary and secondary endpoints by indicating a ...
Breaking Medicine Technology:
(Date:7/21/2017)... ... July 21, 2017 , ... ... students improve their chances of acceptance to a residency in a United States ... earned degrees outside the U.S. , According to data released by the ECFMG®, ...
(Date:7/21/2017)... ... July 21, 2017 , ... West Dermatology is pleased ... Vu, PA-C. Beginning July 17, 2017, Ms. Vu will join West Dermatology’s large network ... experience in dermatology, skin cancer , and more. She graduated from the University ...
(Date:7/21/2017)... ... July 21, 2017 , ... How physicians and ... the rise, say researchers presenting their work at the American Orthopaedic Society ... combination of evaluating the patterns of change in concussion symptom presentation, diagnostic tools ...
(Date:7/20/2017)... ... July 20, 2017 , ... Acute myeloid leukemia (AML) is ... rapidly without treatment. Newly diagnosed patients face intense chemotherapy regimens and a stem ... With such a challenging diagnosis that requires immediate action, patients and caregivers ...
(Date:7/20/2017)... ... ... For individuals with extended hospital stays or who are residents of nursing ... specially designed to accommodate patients with a wide range of ailments or special needs, ... has invented the patent-pending PORTABLE ARM REST, a specially designed armrest that features many ...
Breaking Medicine News(10 mins):